Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2011070172 - AGENTS ANTI-INFLAMMATOIRES DIRIGÉS CONTRE LES ÉPITOPES CITRULLINÉS

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

1 . Antibody specifically reactive with a citrullinated epitope on human PAD4 and/or PAD2 deiminated human histone 2A and/or histone 4, and/or on human PAD2 deiminated human histone H3 for use in the prevention or treatment of Rheumatoid Arthritis wherein the antibody comprises a specific binding domain obtainable from a nucleic acid sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 45.

2. Antibody for use according to claim 1 specifically reactive with a peptide selected from the group consisting of SEQ ID NO: 21 , SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 37 and SEQ ID NO: 38.

3. Antibody for use according to claims 1 or 2 selected from the group consisting of recombinant antibodies, single chain antibodies, Single Chain Variable Fragments (scFvs), fragment antigen binding regions (Fabs), single domain antibodies (sdabs), VHH antibodies, nanobodies, camelids derived single domain antibodies, shark IgNAR derived single domain antibody fragments (VNAR), Anticalins and aptamers.

4. Antibody for use according to claims 1 - 3 wherein the antibody is a monoclonal antibody selected from the group consisting of RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12, RmmAb22.101 , and RmmAb22.102.

5. Method for preventing or treating Rheumatoid arthritis, comprising the step of

administering to a patient in need thereof a therapeutically effective amount of an anti-inflammatory composition comprising an antibody comprising at least one antigen binding region selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 45.

6. Method according to claim 5, wherein the antibody comprises at least a heavy chain domain selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 40, SEQ ID NO: 42 and SEQ ID NO: 44, in combination with a light chain domain selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 39, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43 and SEQ ID NO: 45.

7. Polypeptide comprising an amino acid sequence encoded by a variable heavy or

light chain domain selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 17, SEQ ID NO: 39, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43 and SEQ ID NO: 45.

8. Nucleic acid encoding a polypeptide according to claim 7.

9. Nucleic acid according to claim 8 comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 17, SEQ ID NO: 39, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43 and SEQ ID NO: 45.